Suggested recent literature

Articles found by an AI-assisted PubMed search that may be missing from CancerImmunoDB, shared so that curators and users can see what is being considered.

These articles are not part of the database yet. Each one is a suggestion. The AI judged it from the title and abstract only and can be wrong. A curator reads the full paper, and only then is it added to CancerImmunoDB. A column on this page shows the curators' decision as soon as there is one.

How the list is made

  1. Search. For every year from 2021 to 2026, PubMed is searched for primary research on cancer drugs together with immune terms, and the 100 best matches of each year are taken. Every PubMed ID comes from PubMed itself, never from the AI.
  2. AI screening. Google Gemini reads each title and abstract and says whether the study tests a named anticancer drug and measures its effect on the immune system, the same scope as the database. In a first check, it marked 33 of 40 articles that curators had already accepted as likely relevant (and 1 as uncertain), and it rejected all 20 unrelated cancer articles.
  3. Curator check. Curators read each suggested paper in full and decide. Accepted papers are entered into the database with their doses, techniques and immune terms.

Why this exists: the database holds only about 10 articles a year for 2021–2024, and a plain PubMed search cannot judge whether a paper fits the scope.

574articles screened
360likely relevant
11uncertain
203not relevant
0checked by a curator
0accepted into the database
YearScreenedLikely relevant
20269961
202510081
20249872
20239245
202210052
20218549

Browse the suggestions

Reset Download the full list (CSV)

360 articles shown. “In the database” counts the entries the database already has for each drug the AI named (cell line / animal / patient).

PMIDYearArticleDrugsStudy typeCancer typeIn the databaseCurator status
39009452 2024 Novel insights into paclitaxel's role on tumor-associated macrophages in enhancing PD-1 blockade in breast cancer treatment. Journal for immunotherapy of cancer Likely relevant The study tests paclitaxel and PD-1 blockade in patient data, in vitro macrophages, and in vivo murine models, measuring macrophage cross-presentation and CD8+ T cell responses. paclitaxel; PD-1 blockade Mixed triple-negative breast cancer paclitaxel 21/5/8; PD-1 blockade 0/0/0 Awaiting curator check
39076248 2024 Targeted opening of the blood-brain barrier facilitates doxorubicin/anti-PD-1-based chemoimmunotherapy of glioblastoma. Oncoimmunology Likely relevant The article experimentally tests doxorubicin and anti-PD-1 in a tumor-bearing animal model and reports effects on immunogenic cell death and immunotherapy sensitization. doxorubicin; anti-PD-1 Animal glioblastoma doxorubicin 22/9/0; anti-PD-1 14/36/0 Awaiting curator check
39078050 2024 MS-20 enhances the gut microbiota-associated antitumor effects of anti-PD1 antibody. Gut microbes Likely relevant The study tests the postbiotic MS-20 combined with anti-PD1 antibody in xenograft mouse models and measures immunological changes in the tumor microenvironment like CD8+ T cell infiltration. MS-20 (Symbiota); anti-programmed cell death 1 (PD1) antibody Animal colon and lung cancer MS-20 (Symbiota) 0/0/0; anti-programmed cell death 1 (PD1) antibody 0/0/0 Awaiting curator check
39078728 2024 Cervical Cancer Evades the Host Immune System through the Inhibition of Type I Interferon and CXCL9 by LIF. Clinical cancer research : an official journal of the American Association for Cancer Research Likely relevant Evaluates the impact of LIF blockade and combination with immune checkpoint inhibitors using primary cell cultures, animal models, and patient-derived models, measuring cytokine levels and CD8 T cell infiltration. blocking antibodies against LIF; immune checkpoint inhibitors Mixed cervical cancer blocking antibodies against LIF 0/0/0; immune checkpoint inhibitors 0/0/0 Awaiting curator check
39095793 2024 Genome-wide CRISPR screening identifies tyrosylprotein sulfotransferase-2 as a target for augmenting anti-PD1 efficacy. Molecular cancer Likely relevant The study tests TPST2 genetic loss-of-function and its combinatorial effect with anti-PD1 therapy in mouse syngeneic models, measuring IFNγ signaling, HLA expression, and tumor-infiltrating lymphocytes. anti-PD1 Animal cancer anti-PD1 1/1/0 Awaiting curator check
39107132 2024 Targeting tumor-associated macrophage-derived CD74 improves efficacy of neoadjuvant chemotherapy in combination with PD-1 blockade for cervical cancer. Journal for immunotherapy of cancer Likely relevant The study examines neoadjuvant chemotherapy combined with PD-1 blockade in human samples and in vitro/in vivo models, measuring macrophage phagocytosis and cell-cell interactions. neoadjuvant chemotherapy; PD-1 blockade Mixed cervical cancer neoadjuvant chemotherapy 0/0/0; PD-1 blockade 0/0/0 Awaiting curator check
39137404 2024 YAP1 Inhibition Induces Phenotype Switching of Cancer-Associated Fibroblasts to Tumor Suppressive in Prostate Cancer. Cancer research Likely relevant The study tests anti-PD-1 treatment in vivo alongside genetic targeting, measuring CD8+ T-cell infiltration and activation. anti-PD-1 Animal prostate cancer anti-PD-1 14/36/0 Awaiting curator check
39137819 2024 Functional co-delivery nanoliposomes based on improving hypoxia for increasing photoimmunotherapy efficacy of cold tumors. International journal of pharmaceutics Likely relevant Tests a functional co-delivery nanoliposome (photodynamic therapy and metformin) in animal models and measures immunogenic cell death, T cell activation, and PD-L1 reduction. MET-HMME/CAT-HMME@Nlip; metformin Animal hypoxic cold tumors MET-HMME/CAT-HMME@Nlip 0/0/0; metformin 0/0/0 Awaiting curator check
39168966 2024 A gut microbiota rheostat forecasts responsiveness to PD-L1 and VEGF blockade in mesothelioma. Nature communications Likely relevant Evaluates atezolizumab and bevacizumab in a clinical trial and measures CD8+ T cell infiltration and CD68+ monocytes in patient samples. atezolizumab; bevacizumab Patient malignant mesothelioma atezolizumab 0/0/4; bevacizumab 0/0/7 Awaiting curator check
39181134 2024 Uncovering therapeutic targets for macrophage-mediated T cell suppression and PD-L1 therapy sensitization. Cell reports. Medicine Likely relevant The study screens and tests FDA-approved small-molecule drugs (including COX1/2 inhibitors) in combination with alpha-PD-L1 in tumor models, measuring T cell expansion and CD8+ T cell responses. alpha-PD-L1; cyclooxygenase (COX)1/2 inhibitors Animal triple-negative breast cancer alpha-PD-L1 0/0/0; cyclooxygenase (COX)1/2 inhibitors 0/0/0 Awaiting curator check
39187583 2024 Metal-ion-chelating phenylalanine nanostructures reverse immune dysfunction and sensitize breast tumour to immune checkpoint blockade. Nature nanotechnology Likely relevant The study tests metal-ion-chelating L-phenylalanine nanostructures combined with starvation in tumour-bearing animals and measures their effects on dendritic cell activation and cytotoxic T lymphocyte responses. metal-ion-chelating L-phenylalanine nanostructures; immune checkpoint blockade Animal breast and colorectal tumours metal-ion-chelating L-phenylalanine nanostructures 0/0/0; immune checkpoint blockade 0/1/0 Awaiting curator check
39214650 2024 Eganelisib combined with immune checkpoint inhibitor therapy and chemotherapy in frontline metastatic triple-negative breast cancer triggers macrophage reprogramming, immune activation and extracellular matrix reorganization in the tumor microenvironment. Journal for immunotherapy of cancer Likely relevant The study analyzes paired tumor biopsies and blood samples from clinical trials evaluating eganelisib combined with atezolizumab and chemotherapy, reporting macrophage reprogramming and systemic immune activation. eganelisib; atezolizumab; nab-paclitaxel Patient triple-negative breast cancer eganelisib 0/0/0; atezolizumab 0/0/4; nab-paclitaxel 0/0/0 Awaiting curator check
39223929 2024 Targeting SRSF10 might inhibit M2 macrophage polarization and potentiate anti-PD-1 therapy in hepatocellular carcinoma. Cancer communications (London, England) Likely relevant The study tests a pharmacological inhibitor of SRSF10 (1C8) and PD-1 monoclonal antibodies in vitro, in vivo, and in organotypic spheroids, measuring M2 macrophage polarization and CD8+ T cell responses. 1C8; programmed cell death 1 (PD-1) monoclonal antibodies Mixed hepatocellular carcinoma 1C8 0/0/0; programmed cell death 1 (PD-1) monoclonal antibodies 0/0/0 Awaiting curator check
39225102 2024 Pharmacologic LDH inhibition redirects intratumoral glucose uptake and improves antitumor immunity in solid tumor models. The Journal of clinical investigation Likely relevant Experimentally tests pharmacological LDH inhibition alone and with immune checkpoint blockade in murine cancer models, measuring T cell metabolic changes, infiltration, and function. LDH inhibitors; immune checkpoint blockade Animal melanoma and colon cancer LDH inhibitors 0/0/0; immune checkpoint blockade 0/1/0 Awaiting curator check
39227567 2024 Mitochondrial rewiring with small-molecule drug-free nanoassemblies unleashes anticancer immunity. Nature communications Likely relevant The study experimentally tests small-molecule nanoassemblies and PD-1 blockade in preclinical mouse models, measuring immune-related outcomes like immunogenic cell death, tumor immunogenicity, and antitumor immunity. small-molecule drug-free nanoassemblies; PD-1 blockade Animal cancer small-molecule drug-free nanoassemblies 0/0/0; PD-1 blockade 0/0/0 Awaiting curator check
39244215 2024 Angiotensin receptor blocker attacks armored and cold tumors and boosts immune checkpoint blockade. Journal for immunotherapy of cancer Likely relevant Investigates the role of angiotensin receptor blockers in tumor models and their impact on transforming the tumor microenvironment to enhance ICB. angiotensin receptor blocker; ARB Mixed unspecified angiotensin receptor blocker 0/0/0; ARB 8/1/3 Awaiting curator check
39288081 2024 Combined Autophagy Inhibition and Dendritic Cell Recruitment Induces Antitumor Immunity and Enhances Immune Checkpoint Blockade Sensitivity in Pancreatic Cancer. Cancer research Likely relevant The study tests chloroquine, Flt3 ligand, and anti-LAG3 antibody in mouse models and measures DC activation and T cell infiltration. chloroquine; Flt3 ligand; anti-LAG3 antibody Animal pancreatic cancer chloroquine 3/0/1; Flt3 ligand 0/0/0; anti-LAG3 antibody 0/0/0 Awaiting curator check
39298276 2024 Targeting heterogeneous tumor microenvironments in pancreatic cancer mouse models of metastasis by TGF-β depletion. JCI insight Likely relevant The study tests a TGF-beta trap (AVID200/BMS-986416) combined with anti-PD-1 in PDAC murine models and analyzes immune microenvironment modulation. AVID200/BMS-986416; anti-PD-1 Animal pancreatic ductal adenocarcinoma AVID200/BMS-986416 0/0/0; anti-PD-1 14/36/0 Awaiting curator check
39325056 2024 Hyper-Interferon Sensitive Influenza Induces Adaptive Immune Responses and Overcomes Resistance to Anti-PD-1 in Murine Non-Small Cell Lung Cancer. Cancer immunology research Likely relevant Tests an engineered viral vaccine combined with anti-PD-1 in murine models and measures T cell responses and type I IFN. hyper-IFN-sensitive influenza viral vaccine; anti-PD-1 Animal non-small cell lung cancer hyper-IFN-sensitive influenza viral vaccine 0/0/0; anti-PD-1 14/36/0 Awaiting curator check
39331709 2024 ATR inhibition activates cancer cell cGAS/STING-interferon signaling and promotes antitumor immunity in small-cell lung cancer. Science advances Likely relevant The study tests ATR inhibition combined with PD-L1 blockade or topotecan in cell/mouse models and patient samples, measuring immune readouts such as STING signaling, T cell recruitment, and MHC class I expression. berzosertib; topotecan; programmed death-ligand 1 (PD-L1) inhibitor Mixed small-cell lung cancer berzosertib 0/0/0; topotecan 14/1/0; programmed death-ligand 1 (PD-L1) inhibitor 0/0/0 Awaiting curator check
39358663 2024 PD-1 blockade does not improve efficacy of EpCAM-directed CAR T-cell in lung cancer brain metastasis. Cancer immunology, immunotherapy : CII Likely relevant The study evaluates the administration of anti-PD-1 antibodies and EpCAM-directed CAR T-cells in an in vivo murine model, measuring intratumoral CAR T-cell densities and persistence. anti-PD-1; EpCAM-directed CAR T-cell Animal lung cancer brain metastasis anti-PD-1 14/36/0; EpCAM-directed CAR T-cell 0/0/0 Awaiting curator check
39385035 2024 CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors. Nature Likely relevant Evaluates immune checkpoint inhibitors and chemotherapy in mouse models and patients, assessing T cell subsets and myeloid cell phenotypes. durvalumab; tremelimumab; chemotherapy Mixed non-small-cell lung cancer durvalumab 0/0/2; tremelimumab 0/0/0; chemotherapy 2/0/3 Awaiting curator check
39419025 2024 IRE1α silences dsRNA to prevent taxane-induced pyroptosis in triple-negative breast cancer. Cell Likely relevant Investigates how the ER stress sensor IRE1alpha restricts taxane-induced immunostimulatory effects and pyroptosis in triple-negative breast cancer cells. taxane Cell line Triple-Negative Breast Cancer taxane 1/0/1 Awaiting curator check
39420389 2024 Novel combination therapy using recombinant oncolytic adenovirus silk hydrogel and PD-L1 inhibitor for bladder cancer treatment. Journal of nanobiotechnology Likely relevant The study evaluates the combination of a recombinant oncolytic adenovirus silk hydrogel and a PD-L1 inhibitor in a murine bladder cancer model, measuring T-cell infiltration and immune responses. recombinant oncolytic Adv-loaded silk hydrogel; PD-L1 inhibitor Animal bladder cancer recombinant oncolytic Adv-loaded silk hydrogel 0/0/0; PD-L1 inhibitor 0/0/0 Awaiting curator check
39423284 2024 Programmable bacteria synergize with PD-1 blockade to overcome cancer cell-intrinsic immune resistance mechanisms. Science immunology Likely relevant The study experimentally tests engineered bacteria releasing IFN-gamma combined with PD-1 blockade in tumor-bearing animals and measures their effects on CD4+, CD8+ T cells, and NK cells. IFN-gamma; PD-1 blockade Animal cancer IFN-gamma 0/0/0; PD-1 blockade 0/0/0 Awaiting curator check
← Previous Page 8 of 15 Next →